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Abstract 
Evolving throughout the last century, Gonorrhea has become a superbug, becoming difficult to 
treat. As the second most commonly reported notifiable disease, gonorrhea rates have been 
increasing, despite efforts in prevention and treatment. Populations at risk are mainly MSM and 
FSW. In 2015, men’s gonorrhea rates in the United States were higher compared to women, at 
140.9 and 107.2 per 100,000 population, respectively. Illinois has consecutively had higher rates 
of infection compared to the US, at 133.5 per 100,000 population compared to the US rate of 
123.9 per 100,000 population. The surveillance of gonococcal isolate resistance to current 
antimicrobials began in the 80’s and has continued since, collecting isolates from 25 sites 
nationwide. These isolates assist researchers in finding susceptibility levels and resistance rates 
as they emerge. Over time, however, resistance began emerging with every treatment 
recommended, and gonorrhea is now resistant to most, if not all previous treatments utilized. 
Through each classification of treatment; sulfonamides, penicillin’s, spectinomycin, tetracycline, 
quinolones, and other macrolides, have once succeeded at curing gonorrhea. However, once 
resistance is built, gonorrhea then becomes untreatable. Currently, there are only two 
medications recommended in the treatment of gonococcal infections: Ceftriaxone injection and 
oral Azithromycin. These two medications are the last of many that show efficacy in treating 
gonorrhea, despite increasing resistance. Continued work researching geographic incidence 
similarities and correlations between geographical location, population demographics, and 
spread of resistance over time, may allow further insight into more evasive ways to manage 
prevention efforts against resistance.  
Keywords:  Antimicrobial Resistance, Gonorrhea, Geographical Incidence 
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Geographical Incidence of Antimicrobial Resistant Gonorrhea 
Gonorrhea is a sexually transmitted infection, caused by the bacterium Neisseria 
Gonorrhoeae, with the capacity to develop resistance to previous and current antimicrobials used 
to treat the infection (Unemo & Shafer, 2011, 2014). Due to this bacterium’s ability to evolve, 
Gonorrhea has become increasingly difficult to cure in the most at-risk populations, especially 
among re-infection (Unemo & Shafer, 2011, 2014). If untreated, Gonorrhea can develop into 
serious conditions, such as pelvic inflammatory disease (PID) in women, and epididymitis in 
men. Moreover, Gonorrhea has also been associated with facilitating the acquisition of Human 
Immunodeficiency Virus (HIV) (Centers for Disease Control and Prevention [CDC], 2011; 
Unemo & Shafer, 2011, 2014; World Health Organization [WHO], 2016). More serious risks can 
lead to infertility, as well as the potentially life-threatening risk of disseminated-gonococcal 
infection (DGI) (CDC, n.d.).  
The prevalence of Gonorrhea infection in at-risk populations has become a global burden 
and the focus of public health concern (Unemo & Shafer, 2011, 2014). Treatment of Gonorrhea 
is the responsibility of each nation, as antimicrobial resistant (AMR) Gonorrhea has been 
internationally reported (WHO, 2016). The World Health Organization (WHO) determined in 
2008 that Gonorrhea AMR is no longer a future concept, however, occurring in the present, 
threatening the health of people around the globe (WHO, 2016). Additionally, WHO has 
determined that without an appropriate action plan to combat the prevalence and incidence of 
antimicrobial resistance, gonorrhea will become untreatable (WHO, 2016). Knowing this, WHO 
has developed a draft global action plan to guide countries in the fight against AMR Gonorrhea 
(WHO, 2016). 
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Epidemiology, Testing for Gonorrhea, and Treating Gonorrhea. 
Epidemiology 
On a global scale, there were over 106.1 million cases of Gonorrhea reported in 2008, 
according to the World Health Organization (WHO, 2016). The WHO Western Pacific Region 
had just under 40% of those cases, with a total of 42 million cases reported in 2008 (WHO, 
2016). In the US, Gonorrhea is the second most commonly reported notifiable disease (CDC, 
n.d.). In 2015, the rate of infection for Neisseria Gonorrhoeae was 123.9 per 100,000 population, 
with 395,216 total reported cases nationwide. This was an increase of 12.8% from 2014, with the 
highest reported cases from the South (CDC, n.d.). 
Men are disproportionately at higher risk, especially among the men who have sex with 
men (MSM) population (CDC, n.d.). Additionally, female sex workers (FSW) are also 
considered to be a high-risk population (CDC, n.d.). In 2015, the rate of infection for men in the 
United States was estimated to be 140.9 per 100,000 population, compared to women at 107.2 
per 100,000 population (CDC, n.d.). The burden falls mostly on the age groups of 15-19, 20-24, 
and 25-29, with rates for men at 252.7, 438.7, and 262.9, respectively, while rates for women in 
the same age groups are 567.7, 596.6, and 236.0, respectively (CDC, n.d.). 
Gonorrhea in Illinois 
Illinois has consecutively reported higher rates of Gonorrhea infection, from 2001 to 
2015 (Illinois Department of Public Health [IDPH], 2016). In 2001, the rate of gonorrhea per 
100,000 population was 193.4, (IDPH, 2016). In 2016, the reported number of gonorrhea cases 
in Illinois was 17,130, with a rate of 133.5 per 100,000 population (IDPH, 2016). The city of 
Chicago makes up more than half of the reported cases, with a total of 8,786 cases (IDPH, 2016). 
Cook County (including City of Chicago) was 11,082 cases (IDPH, 2016).   
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Testing for Gonorrhea 
There are multiple ways to test for a gonococcal infection, however, only two tests are 
considered appropriate, and are recommended by the Centers for Disease Control and Prevention 
(CDC). The first test, Nucleic Acid Amplification Test (NAAT), is performed by testing either a 
first catch urine sample or culture sample from the anatomic infection site or both (CDC, n.d.). 
The second testing type is Isolation and Identification (also known as Gram Stain) which is 
typically recommended when the anatomical site of specimen collection is urethral for men or 
vaginal for women (CDC, n.d.). NAAT is considered to be the most effective diagnostic test 
available, however, gram stain is recommended in settings where optimal testing is not available 
(CDC, n.d.). 
There is also a third test, which is less of a feasible option. This method is not testing a 
sample for a diagnosis of gonorrhea, however, is used for antibiotic susceptibility testing. This 
test is performed to determine the efficacy of a specific treatment of Gonorrhea. These tests are 
typically performed when there is a known treatment failure (CDC, n.d.). The test involves 
assessing the gonococcal isolates for antibiotic susceptibility to multiple available treatments. 
When the sample is considered susceptible, the antibiotic can be used in treating the infection. If 
susceptibility diminishes, then the treatment is less effective, or not effective, after a level of 
susceptibility has been diminished (CDC, n.d.). 
Treating Gonorrhea 
Current CDC treatment recommendations of uncomplicated gonococcal infections consist 
of a combination of a single injectable dose of Ceftriaxone 250mg intramuscularly and a single 
oral dose of Azithromycin 1gm (CDC, n.d.; Unemo, del Rio, & Shafer, 2016; Workowski & 
Bolan, 2015). Alternative therapies exist, such as Gentamicin or Gemifloxacin in lieu of 
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Ceftriaxone, when allergies to Cephalosporin’s are present (CDC, n.d.; Workowski & Bolan, 
2015). This therapy has been used for the treatment of Gonorrhea as well as concomitant 
Chlamydia infections for the last few decades. However, decreasing susceptibility and rising 
resistance to the ESC’s have increased the minimum inhibitory concentrations (MICs) required 
to treat Gonorrhea to increase (Unemo et al., 2016; Unemo & Nicholas, 2012; Unemo & Shafer, 
2011, 2014; Workowski & Bolan, 2015).   
Antimicrobial therapy for Gonorrhea treatment is typically given empirically during the 
first visit, requiring the physician to prescribe treatment based on physical examination, and 
reviewing symptoms (Unemo et al., 2016; Workowski & Bolan, 2015). This process follows the 
guidelines for treating Gonorrhea, however, may also be contributing to the rise in AMR 
Gonorrhea (Bala & Sood, 2010; CDC, 2011; Contie, Defibaugh, Steinberg, & Wein, 2014; Katz 
et al., 2012; Kidd et al., 2015; Kirkcaldy et al., 2013; Unemo & Shafer, 2011, 2014; Walsh, 2000; 
WHO, 2016; Workowski & Bolan, 2015).  
 The problems that exist are the current testing procedures required to measure 
susceptibility and resistance to gram-negative cultures obtained require certified laboratories and 
usually take weeks. Culture staining of samples obtained from the patient can be done in a clinic, 
however, are only available a day following the visit (Unemo et al., 2016; Workowski & Bolan, 
2015).  
Timeline of Resistance, Decreased Susceptibility, and Surveillance 
Timeline of Antimicrobial Resistance 
Antimicrobial resistance was observed in the late 1940’s when greater than 90% of 
gonococcal isolates showed signs of resistance to Sulfonamides (Unemo & Shafer, 2011, 2014). 
Although Penicillin and Sulfonamides were discovered in 1928 and 1935, respectively, 
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Sulfonamides became the first antimicrobials used in the treatment of gonorrhea (Unemo & 
Shafer, 2011, 2014). It was not until 1943 when Penicillin was appropriately documented as 
appropriate treatment of gonorrhea. With a higher cure rate (95% of cases with Penicillin 
treatment, versus 80% to 90% with Sulfonamide treatment) and rising resistance to 
Sulfonamides, Penicillin became the new recommended treatment of gonorrhea (Unemo & 
Shafer, 2011, 2014).  
Within 2 years of introduction, Penicillin began showing signs of decreased susceptibility 
(Unemo & Shafer, 2011, 2014; Walsh, 2000). Accumulation of chromosomal resistant detriments 
caused the Minimum Inhibitory Concentrations (MIC) of Penicillin against gonorrhea to rise, 
causing a decrease in susceptibility to Penicillin treatment (Unemo & Shafer, 2011, 2014). 
Although MIC’s were on the rise, and resistance started emerging, Penicillin was still widely 
recommended as the treatment for Gonorrhea, until 1987, mostly due to high-level resistance 
caused by the emergence of β-lactamase-encoding plasmids (CDC, n.d.; Unemo & Shafer, 2011, 
2014).  As time progresses, and newer antibiotics are introduced, decreased susceptibility and 
resistance occurs, creating the need for newer antibiotics, and the inability to treat bacterium that 
develops resistance to current therapies, including Gonorrhea (Bala & Sood, 2010; CDC, 2011; 
Contie et al., 2014; Katz et al., 2012; Kidd et al., 2015; Kirkcaldy et al., 2013; Unemo & Shafer, 
2011, 2014; Walsh, 2000; WHO, 2016). 
Plasmid- and/or chromosomally-mediated resistance to Penicillin is the main contributor 
to Penicillin resistance, and over the last 70-80 years, antimicrobial agents, such as Tetracyclines, 
Fluoroquinolones, Macrolides, and early-generation Cephalosporin’s, have become less effective 
in treating Gonorrhea (Bala & Sood, 2010; CDC, 2011; Contie et al., 2014; Katz et al., 2012; 
Kidd et al., 2015; Kirkcaldy et al., 2013; Unemo & Shafer, 2011, 2014; Walsh, 2000; WHO, 
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2016). Through research, locating how and where these chromosome mediations occur has been 
noted, however, new mutations are often occurring, making it difficult to develop equipment to 
specifically target known mutation sites (Bala & Sood, 2010; CDC, 2011; Contie et al., 2014; 
Katz et al., 2012; Kidd et al., 2015; Kirkcaldy et al., 2013; Unemo & Shafer, 2011, 2014; Walsh, 
2000; WHO, 2016). 
Surveillance 
In 1986, the Gonococcal Isolate Surveillance Program (GISP) was formed to establish the 
selection of therapies based on a rational basis, by monitoring antimicrobial susceptibility trends 
in N.G. strains in the US (CDC, 2016; Kirkcaldy et al., 2013). GISP collaborates with the CDC 
Division of STD Prevention (DSTDP), the Surveillance and Data Management Branch (SDMB), 
the Laboratory Reference and Research Branch (LRRB), the Program Development and Quality 
Improvement Branch (PDQIB), regional labs, selected public health STD programs, and 
associated specialty care clinics in the US (CDC, 2016; Kirkcaldy et al., 2013). GISP analyzes 
demographic and clinical data from positive urethral cultures from the first 25 male patients 
presenting to the sentinel reporting sites, and data for antimicrobial susceptibility (CDC, 2016; 
Kirkcaldy et al., 2013). 
Currently, there are approximately 25-30 sentinel sites located throughout the US, that 
collect urethral isolates obtained from men, to test for antimicrobial susceptibility, and resistance. 
(CDC, 2016; Kidd et al., 2015; Kirkcaldy et al., 2013). Sentinel sites are required to collect 
urethral cultures from the first 25 male patients to be sent to the GISP Laboratories for testing 
(CDC, 2016; Kidd et al., 2015; Kirkcaldy et al., 2013). In addition to GISP, the Gonococcal 
Antimicrobial Surveillance Programme (GASP) was established by WHO to coordinate 
gonococcal antimicrobial resistance surveillance, monitor longitudinal trends in antimicrobial 
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resistance and provide data to inform treatment guidelines (WHO, 2016). This program has been 
implemented globally and works with GISP and local and national departments in the 
surveillance of emerging resistant infections. 
Decreased Susceptibility and Antimicrobial Resistance 
Gonorrhea is currently becoming untreatable due to decreased susceptibility and 
resistance to first-line antimicrobial therapy (Bala & Sood, 2010; CDC, 2011; Contie et al., 2014; 
Katz et al., 2012; Kidd et al., 2015; Kirkcaldy et al., 2013; Unemo & Shafer, 2014; Walsh, 2000; 
WHO, 2016). There has been isolates collected in the recent years that are showing decreased 
susceptibility and resistance to the current treatment regimen (Bala & Sood, 2010; Camara et al., 
2012; Contie et al., 2014; Katz et al., 2012; Kidd et al., 2015; Kirkcaldy et al., 2013; Ohnishi et 
al., 2011; Starnino et al., 2012; Tanaka et al., 2002;  Tanaka, Furuya, Irie, Kanayama, & 
Kobayashi, 2015; Unemo et al., 2012; Unemo & Shafer, 2011, 2014; Walsh, 2000; WHO, 2016; 
Workowski & Bolan, 2015). The first cephalosporin-resistant strain of Gonorrhea was reported 
in Japan, then spread internationally (Bala & Sood, 2010; Camara et al., 2012; Ohnishi et al., 
2011; Starnino et al., 2012; Tankaka et al., 2002; Tanaka et al., 2015; Unemo et al., 2016; Unemo 
et al., 2012; Unemo & Shafer, 2011). This resistant strain caused Japan to discontinue the use of 
Cefixime, and replace it with treatment with Ceftriaxone and Spectinomycin, which are both 
injectables (Bala & Sood, 2010).   
Currently, there is an emerging endemic of decreased susceptibility and resistance to 
current extended-spectrum cephalosporin’s, as well as Azithromycin, in the treatment of 
gonococcal infections (CDC, n.d.; Kidd et al., 2015; Kirkcaldy et al., 2013; Starnino et al., 2012; 
Tanaka et al., 2015; Unemo et al., 2012; Unemo & Shafer, 2014). The MSM population have 
been frequently found to have strains of gonococcal infections associated with an elevated MIC 
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level, resulting in decreased susceptibility, and resistance to current antimicrobial therapies 
(CDC, n.d.; Kidd et al., 2015; Kirkcaldy et al., 2013; Starnino et al., 2012; Tanaka et al., 2015; 
Unemo et al., 2012; Unemo & Shafer, 2014). 
Scope of Project 
GISP Collaboration Project 
The GISP project began as a partnership between the University of Illinois, Urbana-
Champaign (UIUC) and Southern Illinois University School of Medicine (SIU) to determine if 
specific mutation profiles matched a specific resistant microbial. In order to study this, UIUC 
received 130 isolates from the Illinois Department of Public Health, which were collected by the 
Chicago Department of Public Health. The PenA gene would then be sequenced for mutations, 
and matched with a known resistance, to determine if a match could be made. 
The GISP collaboration project then stalled, due to a few factors. The first major factor 
was the lack of funding for the project. Since the project was mostly probative, the work being 
performed was not being funded. The second was due to the priority and importance of 
additional funded projects. Although work has temporarily stopped, the idea and prep work is not 
lost. 
Research Questions 
The next direction for the GISP project was to look into the geographical incidence of 
antimicrobial resistance, as well as the direction in which AMR spread. Recently, antimicrobial 
resistant strains have first been discovered in the Western Pacific or Asian areas, before 
spreading eastward towards Hawaii, Western United States, and the Eastern United States.  
Additionally, what types of populations are being identified in the first AMR strains, and are 
there any similarities among these populations with each incidence of resistance? With this in 
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mind, the following research questions were identified: 1) Where is the geographical location of 
the first reported case of resistance to each line of treatment, and, 2) What are the demographics 
of the population involved in the first reported resistance?  
The first research question requires further research into the timeline of antimicrobial 
resistance, to discover the first reported case of resistance, and follow the timeline for two years 
after, in order to establish a timeline of resistance both in time and geographical manners. This 
allows for a deeper understanding of when and where resistance is beginning, and whether the 
geographical location of infection determines the direction in which resistance is spread over 
time.  
The second research question requires observation of the populations affected by first 
reported antimicrobial resistant gonorrhea, and whether there are any similarities between 
populations during each incidence of first reported resistance. Additionally, over time, are the 
same populations being infected with gonorrhea, and subsequently, the populations becoming the 
first with developing antimicrobial resistant gonorrhea.  
Agency Overview 
The agency included in the fieldwork experience was under the supervision of Wiley 
Jenkins, Ph.D., MPH, Office of Population Science and Policy (OPSP; formally the Population 
Health Science Program) at SIU, located in Springfield, IL, This office sets out to acquire and 
study data to identify disease risk, design and implement strategies to improve health, formulate 
legislative, clinical, and educational policies to provide sustainable solutions, and educate current 
and future health professionals in population health (SIU School of Medicine - Office of Public 
Affairs, 2012).  
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The population reach of SIU is considered to be mostly rural and urban, with a reach of 
about 66 out of 102 total counties in Illinois. These counties are all located within the central and 
southern portion of the state. Illinois has a population of over 12 million, with only about 3 
million residents within this reach (United States Census Bureau, 2010). 
Preliminary Findings and Significance 
Findings 
Reviews published by authors Unemo and Shafer (2011, 2014) that detailed the history of 
Gonorrhea and provided preliminary information to determine a timeline for antimicrobial 
resistance. The authors detailed the history of gonorrhea in a pre-antimicrobial era, as well as 
after microbials were introduced (Unemo & Shafer, 2011, 2014). With this information, other 
specifics around resistance could be used, such as the articles the two authors referenced, 
particularly when specifying when and where first resistance was noted.  
Antimicrobials used in the treatment of Gonorrhea. 
Sulfonamides and Penicillin’s 
Sulfonamides were introduced in the mid-1930's, and according to first reports, began 
producing resistance to treatment by the mid-1940's, as found in studies testing sulfonamide 
susceptibility (Dunlop, 1949). By the late 1940's, however, greater than ninety percent of 
gonococcal isolates showed resistance in vitro to sulfonamides (Unemo & Shafer, 2011, 2014). 
Penicillin's were first introduced prior to the sulfonamide treatment era, however, were 
not widely used as primary treatment for gonococcal infections until 1943, in time for the 
sulfonamides to soon be phased out as primary treatment (Unemo & Shafer, 2011, 2014).  Over 
time, penicillin had a success rate of more than ninety-five percent, which was more than the 
ninety percent once found with sulfonamides, however, over time gonococcal isolates began 
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developing resistance to lower doses of penicillin, thus requiring higher doses to achieve cure 
rates (Amies, 1967; Unemo & Shafer, 2011, 2014).   
Over time, penicillin's continued to be utilized as the first line therapy for treating 
gonococcal infections. Due to increased numbers of isolates showing signs of decreased 
susceptibility, and later, resistance to penicillin's, the United States experienced increasing 
numbers of chromosomally mediated penicillin-resistant gonorrhea. This increase was first seen 
sometime in the mid-1970's, causing the US, and many other countries, to change the 
recommended treatment for gonococcal infections by the mid-1980's (Unemo & Shafer, 2011, 
2014). 
Tetracycline and Spectinomycin 
Tetracycline was used for the treatment of gonorrhea that showed resistance to penicillin 
and was used beginning in the mid-to-late 1940's. After some time, however, gonococcal isolates 
began showing resistance to tetracycline, and by the mid-1980's, tetracyclines became excluded 
from all treatment guidelines (Unemo & Shafer, 2011, 2014). First reported in the United States 
and the Netherlands in 1986, tetracycline resistant gonorrhea became widespread internationally 
(Roberts, Wagenvoort, van Klingreren, & Knapp, 1988; Unemo & Shafer, 2011, 2014).  
Spectinomycin, synthesized in the 1960’s, was used as gonorrhea treatment in isolates 
that showed resistance to penicillin and tetracycline. By 1967, however, gonorrhea isolates began 
showing decreased susceptibility, and eventually resistance, were reported in the Netherlands and 
then in the Philippines by 1981, and in London thereafter (Ison, Littleton, Shannon, Easmon, & 
Phillips, 1983; Stolz, Zwart, & Michel, 1975; Unemo & Shafer, 2011, 2014). Due to increasing 
reports of spectinomycin throughout the 1980’s, this therapy was abandoned internationally, 
even though high-level resistance was exceedingly rare (Unemo & Shafer, 2011, 2014).  
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Quinolones and Macrolides 
Also in the 1960's, Quinolones were introduced as a treatment for gonorrhea (Unemo & 
Shafer, 2011, 2014). Decreased susceptibility developed to original dosing of ciprofloxacin by 
1990, and resistance developed and spread quickly after the doses for ciprofloxacin were raised 
(Tanaka, Kumazawa, Matsumoto, & Kobayashi, 1994; Tanaka et al., 2000; Unemo & Shafer, 
2011, 2014).  
Resistance to quinolone therapy was first reported in the Asian-Western Pacific Region in 
the mid-to-late 1990's, and by 2000, spread to Hawaii, then further through the west and east 
coast of the United States (Iverson et al., 2004; Tanaka et al., 1994; Tanaka et al., 2000; Unemo 
& Shafer, 2011, 2014). This spread of resistance caused the CDC to abandon quinolone therapy 
as recommended treatment for gonorrhea in 2007 (CDC, n.d.; Unemo & Shafer, 2011, 2014). 
Macrolides were introduced in 1952 with the medication Erythromycin, and in 1980, 
Azithromycin, a synthetic derivative of Erythromycin, was introduced (Unemo & Shafer, 2011, 
2014). Early on, erythromycin was found to not be effective in treating gonococcal infections, 
however, azithromycin had a substantially higher activity in treating gonorrhea (Lewis, 2010; 
Unemo & Shafer, 2011, 2014).  
Resistance to Azithromycin was first reported from 1995-2000 in Latin America and has 
been seen internationally despite treatment recommendations or prevention efforts (Lewis, 2010; 
Unemo & Shafer, 2011, 2014). Currently, azithromycin is still used in treating gonococcal 
infections, however as part of a dual therapy regimen (CDC, 2016; Lewis, 2010; Unemo & 
Shafer, 2011, 2014).  
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Expanded-Spectrum Cephalosporin’s 
Cephalosporin’s were discovered early on, during the Sulfonamide era, in 1948, and the 
first useful antibiotic was launched in 1964, Cefalotin (Unemo & Shafer, 2011, 2014). 
Quinolones were no longer recommended for gonococcal treatment, third generation expanded-
spectrum cephalosporin’s (ESCs) took their place (Lewis, 2010; Unemo & Shafer, 2011, 2014). 
The two most common used were injection Ceftriaxone, and oral Cefixime (Lewis, 2010; Unemo 
& Shafer, 2011, 2014). Due to limited availability of oral cefixime, other oral cephalosporins 
were used in Japan, Europe, Hong Kong, and the United States (Lewis, 2010; Unemo & Shafer, 
2011, 2014).  
By 1995, Japan began reporting decreased susceptibility to cephalosporin’s used, and by 
1999 and 2002, resistance was being reported (Akasaka et al., 2001; Ito et al., 2004; Lewis, 
2010, Unemo & Shafer, 2011, 2014). Resistance to ESC’s spread globally, being reported from 
Japan, France, Spain, eventually to United States (Akasaka et al., 2001; Camara et al., 2012; Ito 
et al., 2004; Lewis, 2010; Unemo & Nicholas, 2012; Unemo & Shafer, 2011, 2014). Although 
there has been increasing reports of resistance incidence to ESC's, the use of Ceftriaxone 
intramuscularly is recommended by the CDC in the dual-therapy treatment of gonorrhea, along 
with azithromycin orally (CDC, 2016). 
Significance 
The significance of all the reviews covering antimicrobial resistance over time allows for 
a detailed timeline of when and where resistance developed, and allows for public health officials 
to navigate the changing world of infection treatment. This timeline allows further research into 
the many variables of resistance emerging, such as geographic location, population 
demographics, treatment recommendations, and spread of resistance. This is important to 
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continue into the future, as well as take a further look into the past, in order for public health 
officials to continue the fight against AMR gonorrhea.  
Although prevention efforts are already in place, there needs to be some consideration 
when placing the prevention efforts, so they are not lost among the ever-changing population. 
Currently, the CDC and WHO both have recommendations for preventing and treating 
gonococcal infections and are continuously monitoring infection rates. WHO develops plans 
against antimicrobial resistance, and recently published their 2015 guidelines to help fight 
against antimicrobial resistance (WHO, 2015). 
Next Steps 
The GISP collaboration project is long from complete. This review of past AMR 
gonorrhea has led to the future of researching AMR incidence geographically and determining 
the spread pattern in which resistance is spread. Additionally, the population affected when AMR 
is first reported for each period of resistance, as well as if there are any similarities between 
populations over time. The hope of this research is to pinpoint whether there is a link between 
infection, resistance, and spread, based on the population most infected, and whether there is a 
correlation to the geographical location at the time of resistance. 
Continued work will require more time reviewing studies previously published, showing 
the incidence of AMR by geographical location, as well describe population demographics, to 
give us an understanding of how these similarities may or may not be present. Funding may be 
required, however, may not be necessary for the preliminary phases. The past and current 
treatment policies will be obtained, in order to evaluate best practices and make suggestions to 
improving prevention and treatment of gonorrhea. Additionally, once research has been 
conducted, a systematic review will be published, describing the results of the in-depth research.   
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Conclusion 
As we have seen over the last century, gonorrhea has become increasingly difficult to 
treat, leaving the current population in danger of acquiring untreatable gonorrhea, with risks of 
developing other serious conditions, and HIV. Over time, resistance to previous first line therapy 
has increased, leaving health care practitioners scrambling to find new and improved treatments 
to obtain a cure. Resistance to infection causes our infection rates to increase, despite efforts to 
prevent gonorrhea.  
Moving forward, we need to continue to improve our prevention efforts to aid in 
minimalizing infection rates, while also improving our treatment efforts, whether it be by 
changing testing policies or treatment. Currently, there are only two medications that have 
maintained their effectiveness over time, however, are experiencing their own decreased 
susceptibility rates. Ceftriaxone and Azithromycin, when used in combination, have both been 
capable of curing gonococcal infections.  
With the future of antimicrobials looking dim, currently, with no hope for new prospects 
in the future, the last two remaining treatments are all that is left for treating this once easily 
treated bacterial infection. The looming shadow of untreatable gonorrhea is slowly showing up, 
and gonorrhea has now become this evolving superbug that threatens the health of every 
population globally. 
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